# US 2020/0392452 A1 · Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392452 A1
- Document ID: US20200392452A1
- Status: Published application
- Kind: A1
- Application number: 17/006,054
- Filed: 2020-08-28
- Published: 2020-12-17
- Earliest claimed: 2015-04-20
- Assignees: S-Biomedic NV
- Applicants: S-Biomedic NV
- Inventors: Bernhard Pätzold; Marc Güell
- Web page: https://patentgrep.com/patent/US20200392452A1

## CPC

- C12N 1/20: Bacteria; Culture media therefor
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61P 17/10: Anti-acne agents
- C12N 1/205: Bacterial isolates
- C12Q 1/04: Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)}
- C12Q 1/533: involving isomerase
- A61K 2035/115: {Probiotics}
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- G01N 2333/195: from bacteria
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Aspects of the invention relate to compositions comprising one or more live bacterial strains for topical administration to the skin, wherein the one or more live bacterial strains are Propionibacterium acnes (P. acnes) bacterial strains, and methods for use.

## Claims

### Claim at position 1

1-48. (canceled)

### Claim 49

A method for treating acne, comprising:
topically administering a disinfectant or antibiotic to the skin of a subject with acne; and
topically administering a composition comprising one or more live bacterial strains to the skin of the subject following administration of the disinfectant or antibiotic, wherein the one or more live bacterial strains are Propionibacterium acnes (P. acnes) bacterial strains that produce a low or negligible level of trans-10, cis-12 linoleic acid or exhibit a slow or negligible conversion or degradation of cis-9, cis-12 linoleic acid in media.

### Claim 50 (depends on 49)

The method according to claim 49, wherein the one or more P. acnes bacterial strains produce the same or lower level of trans-10, cis-12 linoleic acid than a P. acnes C3 bacterial strain, or wherein the one or more P. acnes bacterial strains exhibit the same or slower conversion or degradation of cis-9, cis-12 linoleic acid in media than a P. acnes C3 bacterial strain.

### Claim 51 (depends on 49)

The method according to claim 49, wherein the one or more P. acnes bacterial strains have a low expression and/or activity of linoleic acid isomerase.

### Claim 52 (depends on 49)

The method according to claim 49, wherein the one or more P. acnes bacterial strains have the same or lower expression and/or activity of linoleic acid isomerase than a P. acnes C3 bacterial strain.

### Claim 53 (depends on 49)

The method according to claim 49, wherein the one or more P. acnes bacterial strains express no linoleic acid isomerase.

### Claim 54 (depends on 49)

The method according to claim 49, wherein the one or more P. acnes bacterial strains have no linoleic acid isomerase activity.

### Claim 55 (depends on 49)

The method according to claim 49, wherein the one or more P. acnes bacterial strains comprise a loss-of-function mutation in the linoleic acid isomerase gene.

### Claim 56 (depends on 49)

The method according to claim 49, wherein all of the P. acnes bacterial strains within the composition produce low or negligible levels of trans-10, cis-12 linoleic acid or exhibit a slow or negligible conversion or degradation of cis-9, cis-12 linoleic acid in media.

### Claim 57 (depends on 49)

The method according to claim 49, wherein the composition is in the form of a gel, cream, ointment, lotion, serum, powder, aerosol spray or two-component dispensing system.

### Claim 58 (depends on 49)

The method according to claim 49, wherein the composition further comprises one or more of a buffer, thickener or carrier.

### Claim 59 (depends on 49)

The method according to claim 49, wherein the composition is stable at room temperature for at least three months.

### Claim 60 (depends on 49)

The method according to claim 49, wherein the composition is not naturally occurring.

### Claim 61 (depends on 49)

The method according to claim 49, wherein the composition further comprises peptone.

### Claim 62 (depends on 49)

The method according to claim 49, wherein the subject is a human.

### Claim 63 (depends on 49)

The method according to claim 49, wherein one or more of the live bacterial strains is a component of a skin microbiome.

### Claim 64 (depends on 49)

The method according to claim 49, wherein at least one of the live bacterial strains is resistant to the antibiotic or disinfectant.
